HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.

AbstractPURPOSE:
Hypofractionated radiation therapy (HFRT) can induce antitumor T cell responses, particularly in combination with immune checkpoint inhibitors (ICI), but abscopal effects are often precluded by insufficient T cell infiltration of distant, nonirradiated tumors. Additional noncytotoxic, low-dose radiation therapy (LDRT) of distant tumors may enhance the abscopal response, but clinical evidence and preclinical studies for this scenario are lacking.
METHODS AND MATERIALS:
We investigated whether triple treatment consisting of HFRT, ICI, and LDRT could achieve better systemic antitumor response in bilateral mouse tumor models and in patients with stage IV non-small cell lung cancer.
RESULTS:
Our analyses of bilateral mouse tumor models show that HFRT treatment of the primary tumor combined with LDRT treatment of the abscopal tumor and anti-PD1 therapy enhances the abscopal response compared with HFRT/anti-PD1, HFRT/LDRT, or LDRT/anti-PD1 double treatments; complete cure was observed in more than half of the mice treated with triple therapy. The enhanced abscopal effect was associated with increased infiltration of CD8+ effector T cells and upregulated expression of T cell-attracting chemokines. Of 9 patients with metastatic non-small cell lung cancer who were treated with this triple therapy, 3 and 2 patients showed partial responses and stable disease, respectively. Among 9 relatively large (175.7 ± 42.3 cm3) LDRT lesions, 6 lesions decreased by 28% in size, on average.
CONCLUSIONS:
Our study demonstrates preclinically that LDRT of established metastases significantly enhances the abscopal response to HFRT plus ICI. It also shows that additional LDRT was well tolerated by patients and that this treatment profile is effective and worth further study.
AuthorsLimei Yin, Jianxin Xue, Rui Li, Lin Zhou, Lei Deng, Lin Chen, Yan Zhang, Yanying Li, Xuanwei Zhang, Weigang Xiu, Ruizhan Tong, Youling Gong, Meijuan Huang, Yong Xu, Jiang Zhu, Min Yu, Mengqian Li, Jie Lan, Jin Wang, Xianming Mo, Yuquan Wei, Gabriele Niedermann, You Lu
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 108 Issue 1 Pg. 212-224 (09 01 2020) ISSN: 1879-355X [Electronic] United States
PMID32417411 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2020 Elsevier Inc. All rights reserved.
Chemical References
  • Programmed Cell Death 1 Receptor
Topics
  • Adult
  • Animals
  • Carcinoma, Non-Small-Cell Lung (immunology, pathology, radiotherapy)
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunotherapy
  • Lung Neoplasms (immunology, pathology, radiotherapy)
  • Male
  • Mice
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Programmed Cell Death 1 Receptor (immunology)
  • Radiation Dose Hypofractionation
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: